Carmen D. Ng
Research Subjects
Carmen D. Ng has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Joshua C. Toliver
Novo Nordisk Inc., Plainsboro, USA
2 shared publications - Julia Wang
Novo Nordisk Inc., Plainsboro, USA
2 shared publications - Victoria Divino
Novo Nordisk Inc., Plainsboro, USA
2 shared publications - Marcio Buss
Novo Nordisk Inc., Plainsboro, USA
1 shared publication
Latest Publications
- Open Access
- 28 August 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (11) , 5468-5480
Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE)
Introduction Semaglutide 2.4 mg injection (Wegovy®), a glucagon-like peptide-1 (GLP-1) receptor agonist, was approved by the US Food and Drug Administration for weight management in June 2021. Tirzepatide, a glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, was approved for type 2 diabetes mellitus (T2DM; Mounjaro®) in May 2022 and weight management (Zepbound®) in November 2023. Due to limited data on the long-term effectiveness of these medications, this study assessed real-world weight loss with semaglutide 2.4 mg or tirzepatide after 1 year in patients with overweight or obesity and without T2DM. Methods This retrospective cohort study included adults with overweight or obesity and ≥ 1 pharmacy claim for semaglutide 2.4 mg or tirzepatide in the US Komodo Health database between June 4, 2021, and December 15, 2023. Patients had continuous enrollment for 1 year before (baseline period) and 1 year after (follow-up period) the index date (date of treatment initiation) and persistence on therapy (no gap of > 30 days’ supply) during follow-up. Patients with T2DM at baseline were excluded. Weight change from index to 1 year was descriptively assessed. Results Overall, 9916 patients were included (semaglutide 2.4 mg, n = 6794; tirzepatide, n = 3122). Baseline characteristics were descriptively similar for semaglutide 2.4 mg and tirzepatide: mean age was 47.8 and 49.5 years, 79.8% and 77.9% were female, and mean index weight was 104.5 and 104.9 kg, respectively. After 1 year of follow-up, the mean weight loss from baseline with semaglutide 2.4 mg and tirzepatide was − 14.6 and − 17.2 kg, respectively, with percent weight loss of − 14.1% and − 16.5%. Most (83.5%) patients treated with semaglutide 2.4 mg reached the maximum dose (2.4 mg), while 25.9% of patients treated with tirzepatide reached the maximum dose (15 mg). Conclusion Findings suggest semaglutide 2.4 mg and tirzepatide are used in descriptively similar populations and both resulted in clinically meaningful weight loss after 1 year of treatment.
- 28 August 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (11) , 5468-5480
Open AccessReal-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE)
Introduction Semaglutide 2.4 mg injection (Wegovy®), a glucagon-like peptide-1 (GLP-1) receptor agonist, was approved by the US Food and Drug Administration for weight management in June 2021. Tirzepatide, a glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, was approved for type 2 diabetes mellitus (T2DM; Mounjaro®) in May 2022 and weight management (Zepbound®) in November 2023. Due to limited data on the long-term effectiveness of these medications, this study assessed real-world weight loss with semaglutide 2.4 mg or tirzepatide after 1 year in patients with overweight or obesity and without T2DM. Methods This retrospective cohort study included adults with overweight or obesity and ≥ 1 pharmacy claim for semaglutide 2.4 mg or tirzepatide in the US Komodo Health database between June 4, 2021, and December 15, 2023. Patients had continuous enrollment for 1 year before (baseline period) and 1 year after (follow-up period) the index date (date of treatment initiation) and persistence on therapy (no gap of > 30 days’ supply) during follow-up. Patients with T2DM at baseline were excluded. Weight change from index to 1 year was descriptively assessed. Results Overall, 9916 patients were included (semaglutide 2.4 mg, n = 6794; tirzepatide, n = 3122). Baseline characteristics were descriptively similar for semaglutide 2.4 mg and tirzepatide: mean age was 47.8 and 49.5 years, 79.8% and 77.9% were female, and mean index weight was 104.5 and 104.9 kg, respectively. After 1 year of follow-up, the mean weight loss from baseline with semaglutide 2.4 mg and tirzepatide was − 14.6 and − 17.2 kg, respectively, with percent weight loss of − 14.1% and − 16.5%. Most (83.5%) patients treated with semaglutide 2.4 mg reached the maximum dose (2.4 mg), while 25.9% of patients treated with tirzepatide reached the maximum dose (15 mg). Conclusion Findings suggest semaglutide 2.4 mg and tirzepatide are used in descriptively similar populations and both resulted in clinically meaningful weight loss after 1 year of treatment.
- Open Access
- 6 August 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (10) , 5010-5022
Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application
Introduction Semaglutide injection 2.4 mg (Wegovy®; hereafter referred to as semaglutide) was approved by the US Food and Drug Administration in June 2021 for chronic weight management in adults with overweight or obesity. This study aimed to evaluate the real-world long-term effectiveness of semaglutide in combination with the WeGoTogether patient support program with a follow-up period of up to 24 months. Methods This retrospective, noninterventional cohort study included adults with overweight or obesity (body mass index [BMI] ≥ 25.0 kg/m2) who initiated semaglutide and enrolled in WeGoTogether during the study period (6/2021–4/2025). Semaglutide is administered as a once-weekly subcutaneous injection. Patients had ≥ 2 post-index weights, with ≥ 1 weight at 6, 12, 18, and/or 24 months (± 30 days) of follow-up. Self-reported, de-identified data from WeGoTogether were analyzed descriptively. Patient demographics were characterized, and changes in weight and BMI were compared from index to each follow-up time point. Results Overall, 8177 patients met the eligibility criteria, including 7604 (93.0%) patients with a BMI ≥ 30.0 kg/m2. At baseline, the mean age was 49.5 years, mean weight was 234.1 lb, and mean BMI was 38.4 kg/m2; 83.6% of patients were female. Among patients with reported weight at the time points of interest, the mean (standard deviation) percent weight loss was − 13.4% (6.4) at 6 months (n = 6964), − 17.6% (10.2) at 12 months (n = 2050), − 20.3% (11.4) at 18 months (n = 491), and − 20.4% (11.3) at 24 months (n = 325). The proportions of patients achieving ≥ 20% weight loss were 13.1%, 43.3%, 52.5%, and 50.5% at 6, 12, 18, and 24 months, respectively. Similar results were observed for the subgroup with BMI ≥ 30.0 kg/m2. Conclusion The study demonstrated substantial weight loss with semaglutide treatment, including over long-term 18- and 24-month follow-up periods, as reported in the WeGoTogether program. These data suggest patients can achieve clinically meaningful long-term (24 months) weight loss in real-world settings when treated with semaglutide and participating in the WeGoTogether patient support program.
- 6 August 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (10) , 5010-5022
Open AccessReal-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application
Introduction Semaglutide injection 2.4 mg (Wegovy®; hereafter referred to as semaglutide) was approved by the US Food and Drug Administration in June 2021 for chronic weight management in adults with overweight or obesity. This study aimed to evaluate the real-world long-term effectiveness of semaglutide in combination with the WeGoTogether patient support program with a follow-up period of up to 24 months. Methods This retrospective, noninterventional cohort study included adults with overweight or obesity (body mass index [BMI] ≥ 25.0 kg/m2) who initiated semaglutide and enrolled in WeGoTogether during the study period (6/2021–4/2025). Semaglutide is administered as a once-weekly subcutaneous injection. Patients had ≥ 2 post-index weights, with ≥ 1 weight at 6, 12, 18, and/or 24 months (± 30 days) of follow-up. Self-reported, de-identified data from WeGoTogether were analyzed descriptively. Patient demographics were characterized, and changes in weight and BMI were compared from index to each follow-up time point. Results Overall, 8177 patients met the eligibility criteria, including 7604 (93.0%) patients with a BMI ≥ 30.0 kg/m2. At baseline, the mean age was 49.5 years, mean weight was 234.1 lb, and mean BMI was 38.4 kg/m2; 83.6% of patients were female. Among patients with reported weight at the time points of interest, the mean (standard deviation) percent weight loss was − 13.4% (6.4) at 6 months (n = 6964), − 17.6% (10.2) at 12 months (n = 2050), − 20.3% (11.4) at 18 months (n = 491), and − 20.4% (11.3) at 24 months (n = 325). The proportions of patients achieving ≥ 20% weight loss were 13.1%, 43.3%, 52.5%, and 50.5% at 6, 12, 18, and 24 months, respectively. Similar results were observed for the subgroup with BMI ≥ 30.0 kg/m2. Conclusion The study demonstrated substantial weight loss with semaglutide treatment, including over long-term 18- and 24-month follow-up periods, as reported in the WeGoTogether program. These data suggest patients can achieve clinically meaningful long-term (24 months) weight loss in real-world settings when treated with semaglutide and participating in the WeGoTogether patient support program.